3-benzyl-8-fluoro-6-(1H-pyrazol-4-yl)quinazolin-4(3H)-one

ID: ALA4793755

PubChem CID: 155594053

Max Phase: Preclinical

Molecular Formula: C18H13FN4O

Molecular Weight: 320.33

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  O=c1c2cc(-c3cn[nH]c3)cc(F)c2ncn1Cc1ccccc1

Standard InChI:  InChI=1S/C18H13FN4O/c19-16-7-13(14-8-21-22-9-14)6-15-17(16)20-11-23(18(15)24)10-12-4-2-1-3-5-12/h1-9,11H,10H2,(H,21,22)

Standard InChI Key:  MTBGWQNRBPPFHG-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 24 27  0  0  0  0  0  0  0  0999 V2000
   17.2640  -12.1827    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.9651  -12.6071    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.6810  -12.2122    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.2782  -11.3678    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.9913  -10.9704    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.6972  -11.3978    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.4163  -11.0023    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   19.4357  -10.1779    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.7297   -9.7506    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   18.0044  -10.1476    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.3048   -9.7254    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   18.7475   -8.9336    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.4640   -8.5405    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.1591   -8.9686    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.8751   -8.5762    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.8933   -7.7583    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.1897   -7.3345    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.4766   -7.7293    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.5463  -12.5739    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.8030  -12.2238    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.2413  -12.8176    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   15.6325  -13.5353    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   16.4359  -13.3849    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.3806  -12.6346    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  6  2  0
  5  4  2  0
  4  1  1  0
  5  6  1  0
  5 10  1  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  1  0
 10 11  2  0
  9 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 13  1  0
  1 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  1  0
 22 23  2  0
 23 19  1  0
  3 24  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4793755

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 320.33

Molecular Weight (Monoisotopic): 320.1073

AlogP: 2.97

#Rotatable Bonds: 3

Polar Surface Area: 63.57

Molecular Species: NEUTRAL

HBA: 4

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 2.31

CX LogP: 2.77

CX LogD: 2.77

Aromatic Rings: 4

Heavy Atoms: 24

QED Weighted: 0.63

Np Likeness Score: -1.68

References

1. Xu G,Gaul MD,Liu Z,DesJarlais RL,Qi J,Wang W,Krosky D,Petrounia I,Milligan CM,Hermans A,Lu HR,Huang DZ,Xu JZ,Spurlino JC.  (2020)  Hit-to-lead optimization and discovery of a potent, and orally bioavailable G protein coupled receptor kinase 2 (GRK2) inhibitor.,  30  (23): [PMID:33038544] [10.1016/j.bmcl.2020.127602]

Source

Source(1):

• Scientific Literature